C4 Therapeutics Phase 1 cemsidomide shows 50% ORR at 100 µg in RRMM; Phase 2 planned Q1 2026

C4 Therapeutics, Inc.

50% ORR at 100 µg and 40% ORR at 75 µg cemsidomide + dex in heavily pre-treated RRMM; median DOR 9.3 mo overall.
No cemsidomide-related discontinuations; minimal dose reductions (6%); low rates of febrile neutropenia (4% Grade 3, 1% Grade 4).
Phase 2 single-arm registrational trial in 4th line+ starts Q1 2026; Phase 1b with BCMA BiTE in 2nd line+ starts Q2 2026.
72 patients enrolled; median 7 prior therapies; 75% had prior CAR-T or T-cell engager therapy; data cutoff July 23, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.